ImmunogenX and Mayo Clinic celiac condition examine published in Gastroenterology

Newport Seashore, CA–(company wire)–ImmunogenX is delighted to announce the thriving completion of the CeliacShield™ demo (NCT03585478) focused on the therapy of people with celiac disorder (CeD) and will be released in a premier journal. Department of Gastroenterology and are entitled:

Latiglutenase guards mucous membranes and lowers symptom severity in celiac clients uncovered to gluten problem

doi.org/10.1053/j.gastro.2022.07.071

This get the job done was done at the Mayo Clinic underneath the supervision of Principal Investigator Joseph Murray, M.D., with the pursuing success:

  • Verified results of a previous European analyze (NCT01255696) demonstrating that latiglutenase safeguards patients from mucosal destruction brought on by nutritional gluten.

  • Making use of a celiac condition-specific patient-described consequence (Professional) instrument, we shown that latiglutenase also shields versus the scientific adverse consequences of gluten usage.

  • The 1st-at any time scientific demo use of gluten immunogenic peptide (GIP) in a urine assay demonstrates ~95% clearance (p < 0.0001) of gluten in the stomach by latiglutenase.

said Peter HR Green, M.D., of Columbia University. Despite adhering to a strict gluten-free diet, these patients with celiac disease continue to be exposed to gluten in their daily lives and suffer the consequences despite their best dietary efforts. increase.”

Jack Syage, PhD and CEO of ImmunogenX, said: Our mission to improve the lives of people with celiac disease is inspired by members of our team who suffer from the disease and is our driving force to achieve success that benefits everyone else. .

This clinical trial was sponsored by the National Center for Complementary and Integrative Medicine (NCCIH) at the National Institutes of Health (NIH). *For more information, visit Celiacshield.com.

*The content of this news release is the responsibility of ImmunogenX and does not necessarily represent the official views of the National Institutes of Health.

About ImmunogenX

ImmunogenX, Inc. is a clinical-stage biopharmaceutical company founded in 2013 and supported by a world-renowned team of clinicians, scientists and celiac disease research advisors. The company is developing latiglutenase (IMGX003) for the treatment of celiac disease. ImmunogenX is a diagnostic tool for celiac disease management (CypCel™) that minimally invasively monitors villous health to track recovery in celiac patients adhering to a gluten-free diet and other therapies is also being developed. www.immunogenx.com

See also  GERD in infants and kids: triggers, analysis, and treatments

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.